In recent trading session, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw 1.0 million shares changing hands at last check today with its beta currently measuring 1.16. Company’s recent per share price level of $8.43 trading at $0.4 or 4.92% at last check today assigns it a market valuation of $1.14B. That most recent trading price of AUPH’s stock is at a discount of -26.57% from its 52-week high price of $10.67 and is indicating a premium of 38.32% from its 52-week low price of $5.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.08 million shares which gives us an average trading volume of 1.22 million if we extend that period to 3-months.
For Aurinia Pharmaceuticals Inc (AUPH), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) trade information
Upright in the green today for gaining 4.92%, in the last five days AUPH remained trading in the green while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $8.43 price level, adding 4.2% to its value on the day. Aurinia Pharmaceuticals Inc’s shares saw a change of 48.85% in year-to-date performance and have moved 6.38% in past 5-day. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) showed a performance of 3.37% in past 30-days. Number of shares sold short was 10.53 million shares which calculate 8.4 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 29.75% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would jump 28.83% in reaching the projected high whereas dropping to the targeted low would mean a gain of 28.83% for stock’s current value.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s Major holders
Insiders are in possession of 9.84% of company’s total shares while institution are holding 47.38 percent of that, with stock having share float percentage of 52.55%. Investors also watch the number of corporate investors in a company very closely, which is 47.38% institutions for Aurinia Pharmaceuticals Inc that are currently holding shares of the company. ARMISTICE CAPITAL, LLC is the top institutional holder at AUPH for having 11.14 million shares of worth $63.59 million. And as of 2024-06-30, it was holding 7.7696 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 9.27 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.4692 of outstanding shares, having a total worth of $52.94 million.
On the other hand, iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Apr 30, 2025 , the former fund manager was holding 3.31 shares of worth $28.23 million or 2.45% of the total outstanding shares. The later fund manager was in possession of 1.33 shares on Feb 28, 2025 , making its stake of worth around $11.36 million in the company or a holder of 0.99% of company’s stock.
